CureSearch for Children's Cancer funds and supportstargeted and innovative children's cancer research with measurableresults, and is the authoritative source of information and resourcesfor all those affected by children's cancer.
For Immediate Release: January 13, 2011Contact: Erica Neufeld(240) 235-2201
Bethesda, MD – Stuart Siegel, MD, Director, Children’s Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles was named Chair of the Board of CureSearch for Children’s Cancer on last week, a leading pediatric oncology research foundation.
Siegel has been a longtime board member of CureSearch for Children’s Cancer and has worked to ensure that the organization continues to support the cutting edge research of the Children’s Oncology Group (COG), a collaborative research group of more than 210 member hospitals worldwide. In the U.S., Children’s Oncology Group hospitals treat more than 90 percent of children with cancer.
"I am honored to have the opportunity to help CureSearch achieve its goal of extending the hope of a cure to all infants, children and teens with cancer by supporting the research of the Children's Oncology Group,” says Siegel. “As a pediatric hematologist-oncologist, I know that the remarkable progress we have made over the past 50 years, and that which we will make in the future, ultimately depends on the research carried out by COG and its member institutions. The "fuel" for that research is the support that CureSearch can and must provide."
Progress has been made in the survival rates of children’s cancer in recent decades. Forty years ago, the overall survival rate was approximately 20 percent and now it is nearly 80 percent. Still, more than 13,500 children are diagnosed each year and one in five children loses his or her battle with cancer. Many children also experience long-term effects from treatment, including secondary cancers.
For 10 years CureSearch has supported the research of the Children’s Oncology Group by raising funds from its national office in Bethesda, MD. In the last year, CureSearch has expanded its operation to include five regional fundraising offices and the organization’s revenue has increased significantly. John Lehr, president and CEO of CureSearch for Children’s Cancer is excited about Dr. Siegel’s new role and how it will help move the organization forward. “Dr. Siegel is a highly regarded pediatric oncologist. As a leader in this field for many years, Dr. Siegel truly understands the critical role that fundraising plays in advancing children’s cancer research,” said Lehr. “I am looking forward to working with him as we continue to expand the presence of CureSearch and the amount of money available for children’s cancer research.”
Also appointed to a board leadership role was former Congresswoman Deborah Pryce, who will serve as Vice Chair. Congresswoman Pryce is a co-founder of Hope Street Kids, now a program of CureSearch for Children’s Cancer. During her time in Congress she was instrumental in passing the Caroline Pryce Walker Conquer Childhood Cancer Act. This Act authorizes congress to allocate up to $30 million a year in children’s cancer research to the National Cancer Institute. Through its advocacy efforts, CureSearch is actively seeking to realize the funding of this Act.
# # #
About Stuart Siegel, MDDr. Siegel is the founding director of the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles and has served as the Division Head of the Pediatric Hematology-Oncology program at the hospital for 34 years. He has also been Associate Director for Pediatric Oncology at the USC/Norris Comprehensive Cancer Center for 20 years and oversaw the development of one of the largest pediatric translational cancer research programs in the nation and its integration into the scientific program of the Cancer Center, especially in the areas of Developmental Therapeutics, Tumor Microenvironment and Leukemia/Lymphoma. In addition, Dr. Siegel is the Principal Investigator for the USC-CHLA Institute for Pediatric Clinical Research which conducts a drug development program for pediatric leukemias and lymphomas, pre-clinical efficacy studies and initial Phase 1 testing in a 33-member international clinical trials consortium TACL.
About CureSearch for Children’s CancerCureSearch for Children’s Cancer funds the lifesaving, collaborative research of the Children’s Oncology Group, the largest children’s cancer research organization in the world. With more than 5,000 physicians, nurses and researchers at more than 200 hospitals in North America and worldwide, this group treats 90 percent of children with cancer in the U.S.
Shelby HammondCommunications Manager Email Shelby(240) 235-2205